Abstract 197P
Background
This study aimed to investigate characteristics, treatment patterns and clinical outcomes of Chinese patients with UAM GA/GEJA in real-world settings.
Methods
This was a multicenter, retrospective, observational study using electronic medical records from four tertiary hospitals. Adult patients who were diagnosed with UAM GA/GEJA between Jan 1, 2017 and Dec 31, 2020 and had ≥1 inpatient admission related to UAM GA/GEJA from diagnosis to Aug 31, 2021 were included. Descriptive statistics were applied to summarize the data and Kaplan- Meier method was used to describe duration of treatment (DoT) and progression-free survival (PFS) by each line of therapy.
Results
Of the 2,745 eligible patients (median age 62 years, 69.2% male), 97.3% had a diagnosis of GA, 94.0% had stage IV disease, and 43.4% had peritoneum metastasis at diagnosis. Of the 2,745 patients, 1,902 (69.3%) received first-line (1L) therapy. Of the 1,902 patients, 729 (38.3%) subsequently received second-line (2L) therapy and 284 (14.9%) received third-line (3L) therapy. The majority of patients received chemotherapy alone in 1L and 2L settings (84.1% in 1L, 63.6% in 2L, 41.4% in 3L). Targeted therapy-based regimen (13.7% in 1L, 30.3% in 2L, 49.2% in 3L) and immunotherapy-based regimen (3.1% in 1L, 8.7% in 2L, 18.5% in 3L) were used more often in 3L setting. The most frequently used treatment regimen in 1L, 2L, and 3L were fluoropyrimidine (FP) plus platinum (44.5%), FP plus taxanes (16.5%), and anti-angiogenic tyrosine kinase inhibitors alone (18.2%), respectively. Median (95% CI) DoT (4.4 months [4.2, 4.8] in 1L, 3.1 months [2.7, 3.6] in 2L, 2.4 months [2.0, 2.9] in 3L) and PFS (6.5 months [6.1, 6.9] in 1L, 4.2 months [3.7, 4.5] in 2L, 3.2 months [2.8, 3.7] in 3L) decreased progressively with each advancing line of therapy.
Conclusions
Patients treated in 1L and 2L mainly received chemotherapy alone at that time. DoT and PFS were generally short in all lines of therapy, which suggests the need for more effective new treatment options.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
G. Segall, L. Zhou, C. Zhou, M. Khanal: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company; Financial Interests, Personal, Stocks/Shares: Eli Lilly and Company. All other authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract